Integra LifeSciences HoldingsIART
▼ NegativeCapitalSupplyrelevance
Plans a $600M seven-year Senior Secured Term Loan B as part of a refinancing to pay down debt and cover fees.
Impact on assets 1
Biotech & Genomic Medicine
Integra LifeSciences HoldingsTheme Impact 1
Off-coverage companies
Related news
United States
New Zealand▲
Symphony Trial Shows Faster Diabetic Foot Ulcer Healing
Aroa Biosurgery Limited announced positive results from a prospective, multicenter randomized controlled trial of Symphony, published in the International Wound Journal. The study enrolled 143 patients across 10 U.S. sites and found that 55% of diabetic foot ulcers achieved complete wound closure within 12 weeks when Symphony was added to standard of care, compared with 35% receiving standard of care alone, a result with a p-value of 0.039. Mean time to complete wound closure was reduced by 7.8 days, to 65.4 days with Symphony plus standard of care versus 73.2 days with standard of care alone, a result with a p-value of 0.041. The trial enrolled patients with challenging Wagner Grade 1 or 2 diabetic foot ulcers, and patients were randomly assigned to receive weekly Symphony plus standard of care or standard of care alone for up to 12 weeks or until complete wound closure. Lead investigator Dr David Armstrong said the trial demonstrates that combining a novel extracellular matrix bioscaffold with high molecular weight hyaluronic acid can significantly improve wound healing when added to good standard of care. AROA CEO Brian Ward called the results a major milestone for Symphony and said the publication places Symphony among a small group of CAMPs with Level I effectiveness data, strengthening its differentiation and commercial value proposition.
About megatrends
Biotech & Genomic Medicine › Regenerative Medicine & Tissue Engineering ▲Technology
United StatesElutia Receives Full $8 Million Boston Scientific Escrow Payment, Now Funded Into 2029
Elutia Inc. has received the full $8 million held in escrow from Boston Scientific Corporation tied to the sale of its BioEnvelope business, with the payment released on schedule and with no claims. The escrow release follows an indemnity holdback period that began with the October 1, 2025 closing of the $88 million transaction, and it marks the third of three funding milestones Elutia outlined in its second quarter earnings release, after the Avenue Capital facility closed on August 11, 2026 and the SimpliDerm divestiture closed on August 17, 2026. Elutia said it believes it is funded through the first full year of the NXT-41x commercial launch and into 2029 without the need for an equity offering, and it continues to expect a favorable FDA clearance decision for NXT-41x in the first half of 2027. NXT-41x, the company's next-generation antibiotic-eluting surgical matrix, is being developed for the $1.5 billion U.S. plastic and reconstructive surgery market, where complex procedures can carry post-operative infection rates of 15 to 20 percent. In an independent blinded survey of 50 board-certified plastic and reconstructive surgeons reported in August 2026, 86 percent said the matrices they use today increase infection risk and 96 percent expressed interest in incorporating NXT-41x into their practice.
About megatrends
Biotech & Genomic Medicine › Regenerative Medicine & Tissue Engineering Capital
ELUT · Capital · Positive Elutia received the full $8M escrow payment, the last of three funding milestones, and says it is funded into 2029 without an equity offering.
United States▲
AVITA Medical Fair Value Raised to $12.29 After PermeaDerm Data and Q2 Beat
AVITA Medical's updated valuation work now points to a fair value of $12.29, up from the prior $11.06, following the PermeaDerm I data and recent quarterly results. TD Cowen lifted its price target to US$14 from US$12 after a KOL webinar that it said highlighted a clear economic benefit for PermeaDerm compared with allograft with comparable clinical outcomes. BTIG increased its target to US$11 from US$7, citing PermeaDerm I results showing a 70% economic advantage versus allograft based on product cost per % TBSA treated and a 96% reduction in preparation time, and also upgraded AVITA Medical to Buy from Neutral with a US$7 target, pointing to stabilizing reimbursement and U.S. RECELL volume up about 11% sequentially. Lake Street moved its target to US$8 from US$6 after what it called a significant Q2 beat and guide up. The revised fair value reflects a revenue growth assumption of 25.61%, a net profit margin assumption of 17.25%, a future P/E assumption of 19.18x, and a discount rate of 7.72%.
About megatrends
Biotech & Genomic Medicine › Regenerative Medicine & Tissue Engineering ▲Demand
IsraelCollPlant Biotechnologies Posts Q2 GAAP EPS of -$1.89 on $0.11M Revenue
CollPlant Biotechnologies reported second-quarter GAAP earnings per share of -$1.89 on revenue of $0.11 million, a 38.9% increase year over year. Cash and cash equivalents as of June 30, 2026, stood at $2.6 million. Cash used in operating activities during the six months ended June 30, 2026, was $5.4 million, compared with $3.6 million during the six months ended June 30, 2025. The company reaffirmed its fiscal 2026 outlook.
About megatrends
Biotech & Genomic Medicine › Regenerative Medicine & Tissue Engineering Capital
Israel
Germany▼
CollPlant Completes LightSolver Acquisition, Posts $2.7 Million Q2 Net Loss
CollPlant Biotechnologies completed its acquisition of photonic computing pioneer LightSolver in September 2026, a deal that closed after the quarter and therefore is not reflected in the company's reported second-quarter results. For the three months ended June 30, 2026, CollPlant reported GAAP revenues of $108,000, down from $179,000 a year earlier on lower sales of rhCollagen-based products, and a GAAP net loss of $2.7 million, or $1.89 basic loss per share, compared with a net loss of $3.3 million, or $2.83 basic loss per share, in the prior-year quarter. Six-month GAAP revenues fell to $181,000 from $2.2 million, a decline the company attributed primarily to a $2.0 million development milestone payment from a former business collaborator recognized in 2025 that did not recur, while the six-month GAAP net loss widened to $5.8 million, or $4.13 basic loss per share, from $4.8 million, or $4.12 basic loss per share. CollPlant said joint research by LightSolver and the High-Performance Computing Center Stuttgart, published in the ACM proceedings, demonstrated projected time-to-solution acceleration ranging from approximately 40 times to more than 80,000 times compared with state-of-the-art GPU-based algorithms, depending on the benchmark problem and algorithm evaluated. Following the closing, CollPlant appointed LightSolver CEO and co-founder Dr. Ruti Ben Shlomi to its Board of Directors, and the company ended the quarter with $2.6 million in cash and cash equivalents.
About megatrends
Biotech & Genomic Medicine › Regenerative Medicine & Tissue Engineering ▼Technology
United StatesIntegra LifeSciences Q2 2026 Adjusted EPS Jumps 24.4% as Braintree Ramps Up
Integra LifeSciences Holdings Corporation reported second-quarter 2026 adjusted EPS growth of 24.4% year over year, exceeding management's guidance range, as the company's Specialty Surgery segment grew 1.6% organically to $309.3 million. Adjusted gross margin improved 60 basis points to 61.3% and adjusted EBITDA margin expanded 160 basis points to 18.7%, while management kept its full-year 2026 adjusted EPS guidance unchanged at $2.40-$2.50. The company's Tissue Reconstruction segment posted revenues of $109.5 million, down 2% organically, as DuraSorb growth and PriMatrix gains were offset by lower Integra Skin and MicroMatrix sales. Integra ended the quarter with total liquidity of about $496 million, including $274 million of cash and short-term investments, but net debt remained high at $1.60 billion and total leverage of 4.1X stayed above management's 2.5X-3.5X target range. Management also lowered full-year reported revenue guidance to $1.654-$1.695 billion from $1.662-$1.702 billion solely because of a stronger U.S. dollar.
About megatrends
Biotech & Genomic Medicine › Regenerative Medicine & Tissue Engineering Capital
IART · Capital · Positive Q2 2026 adjusted EPS jumped 24.4% YoY, beating guidance, with gross and EBITDA margins expanding